Related references
Note: Only part of the references are listed.Genetic Variants Predisposing Most Strongly to Type 1 Diabetes Diagnosed Under Age 7 Years Lie Near Candidate Genes That Function in the Immune System and in Pancreatic beta-Cells
Jamie R. J. Inshaw et al.
DIABETES CARE (2020)
Gene polymorphisms of VEGF and VEGFR2 are associated with the severity of Hashimoto's disease and the intractability of Graves' disease, respectively
Mami Okamoto et al.
ENDOCRINE JOURNAL (2020)
Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides
Tammy Price-Troska et al.
INVESTIGATIONAL NEW DRUGS (2019)
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Kevan C. Herold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis
Agnieszka Paradowska-Gorycka et al.
BIOMOLECULES (2019)
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
Michelle Rosenzwajg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Association between vascular endothelial growth factor receptor 2 rs11941492 C/T polymorphism and Chinese Han patients in rheumatoid arthritis
Zhicheng Yang et al.
MEDICINE (2019)
Regulatory T cells in the treatment of disease
Amir Sharabi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes
Eleonora Seelig et al.
JCI INSIGHT (2018)
Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012
Elizabeth J. Mayer-Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An immune clock of human pregnancy
Nima Aghaeepour et al.
SCIENCE IMMUNOLOGY (2017)
Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial
John A. Todd et al.
PLOS MEDICINE (2016)
Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes
Aixin Yu et al.
DIABETES (2015)
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients
Michelle Rosenzwajg et al.
JOURNAL OF AUTOIMMUNITY (2015)
Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs
Mahzad Akbarpour et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
David Klatzmann et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
Alana A. Kennedy-Nasser et al.
CLINICAL CANCER RESEARCH (2014)
B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year Results
Mark D. Pescovitz et al.
DIABETES CARE (2014)
IL-2: The First Effective Immunotherapy for Human Cancer
Steven A. Rosenberg
JOURNAL OF IMMUNOLOGY (2014)
Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
Teodora P. Staeva et al.
DIABETES (2013)
Limitations of IL-2 and Rapamycin in Immunotherapy of Type 1 Diabetes
Audrey Baeyens et al.
DIABETES (2013)
Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial
Agnes Hartemann et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Interleukin 2 in the Pathogenesis and Therapy of Type 1 Diabetes
Michelle Rosenzwajg et al.
CURRENT DIABETES REPORTS (2012)
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs Yet Transiently Impairs β-cell Function
S. Alice Long et al.
DIABETES (2012)
Administration of CD4+CD25highCD127- Regulatory T Cells Preserves β-Cell Function in Type 1 Diabetes in Children
Natalia Marek-Trzonkowska et al.
DIABETES CARE (2012)
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
David Saadoun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Immune intervention in type 1 diabetes
Aaron W. Michels et al.
SEMINARS IN IMMUNOLOGY (2011)
Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus
Douglas O. Sobel et al.
ACTA DIABETOLOGICA (2010)
Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+ CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects
S. Alice Long et al.
DIABETES (2010)
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Kajsa Wing et al.
NATURE IMMUNOLOGY (2010)
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
Qizhi Tang et al.
IMMUNITY (2008)
CD3-specific antibodies: a portal to the treatment of autoimmunity
Lucienne Chatenoud et al.
NATURE REVIEWS IMMUNOLOGY (2007)
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn et al.
BLOOD (2006)
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes
QZ Tang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice
A Rabinovitch et al.
DIABETES (2002)
Share Paper
